Bayer is discontinuing its Calantic Digital Solutions AI platform and ceasing Blackford Analysis services, signaling a major retreat from the radiology AI platform sector.
Key Details
- 1Bayer will exit the radiology AI software platform business, discontinuing Calantic and Blackford Analysis offerings.
- 2Calantic was launched in 2022 and built on Blackford's platform, which Bayer fully acquired in 2023.
- 3Blackford's platform currently hosts over 150 third-party AI apps from more than 60 developers across multiple clinical domains.
- 4A dedicated Bayer team will handle the transition, honoring existing contracts; future sale plans for Blackford are not confirmed.
- 5Industry experts suggest the move may trigger a consolidation wave in the radiology AI platform market and signal underlying adoption and integration challenges.
Why It Matters
Bayer’s withdrawal removes a key player and nearly 10% of spending from the global radiology AI platform ecosystem, raising concerns about the long-term viability of the platform model and potentially slowing broader AI adoption in radiology due to market uncertainty and loss of confidence.
Source
AuntMinnie
Related News
•HealthExec
How AI Is Reshaping Healthcare Workforce: Roles at Risk and Emerging Opportunities
AI is poised to replace administrative and documentation-heavy healthcare jobs while creating new data and AI-focused roles, with most patient-facing and complex clinical positions remaining secure.
•Cardiovascular Business
AI Is Quietly Embedded in Cardiac Imaging Workflows
AI is now seamlessly integrated into cardiac imaging, often unnoticed by clinicians.
•AuntMinnie
Radiology AI Moves From Hype to Operational Accountability
Radiology leaders are shifting focus from curiosity about AI to demanding measurable, accountable operational impact.